Skip to main content
SpringerLink
Log in

Sexualhormone

  • Chapter
Arzneiverordnungs-Report 2016

  • 2095 Accesses

Zusammenfassung

Die wichtigsten Gruppen der Sexualhormone sind Östrogenpräparate und Kontrazeptiva. Danach folgen mit weitem Abstand Androgene, Antiandrogene und Gestagene. Die Verordnungen der Östrogenpräparate zur Hormontherapie in der Postmenopause sind seit 1999 um 78% zurückgegangen.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 64.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • American College of Obstetricians and Gynecologists (2013): Committee opinion no. 556: Postmenopausal estrogen therapy: route of administration and risk of venous thromboembolism. Obstet Gynecol 121: 887–890

    Article  Google Scholar 

  • Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, Jette AM, Eder R, Tennstedt S, Ulloor J, Zhang A, Choong K, Lakshman KM, Mazer NA, Miciek R, Krasnoff J, Elmi A, Knapp PE, Brooks B, Appleman E, Aggarwal S, Bhasin G, Hede-Brierley L, Bhatia A, Collins L, LeBrasseur N, Fiore LD, Bhasin S (2010): Adverse events associated with testosterone administration. N Engl J Med 363: 109–122

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Biglia N, Carinelli S, Maiorana A, D’Alonzo M, Lo Monte G, Marci R (2014): Ulipristal acetate: a novel pharmacological approach for the treatment of uterine fibroids. Drug Des Devel Ther 8: 285–292

    CAS  PubMed  PubMed Central  Google Scholar 

  • Bundesminister für Gesundheit (2015): Verordnung zur Änderung der Arzneimittelverschreibungsverordnung und der Apothekenbetriebsordnung vom 6. März 2015. Bundesgesetzblatt 2015, Teil I, Nr. 10, Seite 278, ausgegeben zu Bonn am 13. März 2015

    Google Scholar 

  • Canonico M, Oger E, Plu- Bureau G,, Conard J, Meyer G, Lévesque H, Trillot N, Barrellier MT, Wahl D, Emmerich J, Scarabin PY; Estrogen and Thromboembolism Risk (ESTHER) Study Group (2007): Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 115: 840–845

    Google Scholar 

  • Cauley JA, Seeley DG, Ensrud K, Ettinger B, Black D, Cummings SR (1995): Estrogen replacem ent therapy and fractures in older women. Ann Intern Med 122: 9–16

    Article  CAS  PubMed  Google Scholar 

  • Cheng L, Gulmezoglu AM, Oel CJ, Piaggio G, Ezcurra E, Look PF (2004): Interventions for emergency contraception. Cochrane Database Syst Rev. 2004; (3): CD001324

    Google Scholar 

  • Chlebowski RT, Anderson GL, Gass M, Lane DS, Aragaki AK, Kuller LH, Manson JE, Stefanick ML, Ockene J, Sarto GE, Johnson KC, Wactawski-Wende J, Ravdin PM, Schenken R, Hendrix SL, Rajkovic A, Rohan TE, Yasmeen S, Prentice RL; WHI Investigators (2010): Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 304: 1684–1692

    Article  CAS  PubMed  Google Scholar 

  • Cogliano V, Grosse Y, Baan R, Straif K, Secretan B, El Ghissassi F; WHO International Agency for Research on Cancer (2005): Carcinogenicity of combined oestrogen-progestagen contraceptives and menopausal treatment. Lancet Oncol 6: 552–553

    Article  PubMed  Google Scholar 

  • Creinin MD, Schlaff W, Archer DF, Wan L, Frezieres R, Thomas M, Rosenberg M, Higgins J (2006): Progesterone receptor modulator for emergency contraception: a randomized controlled trial. Obstet Gynecol 108: 1089–1097

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • de Bastos M, Stegeman BH, Rosendaal FR, Van Hylckama Vlieg A, Helmerhorst FM, Stijnen T, Dekkers OM (2014): Combined oral contraceptives: venous thrombosis. Cochrane Database Syst Rev. 2014 Mar 3;3:CD010813. doi:10.1002/14651858.CD010813.pub2. Review.

    PubMed  Google Scholar 

  • Deutsche Gesellschaft für Gynäkologie (Hrsg) (2009): Hormontherapie in der Peri- und Postmenopause (HT). Internet: http://www.awmf.org/leitlinien/detail/ll/015-062.html

  • Dinger J, Assmann A, Möhner S, Minh TD (2010): Risk of venous thromboembolism and the use of dienogest- and drospirenone-containing oral contraceptives: results from a German case-control study. J Fam Plann Reprod Health Care 36: 123–129

    Article  PubMed  Google Scholar 

  • Ford O, Lethaby A, Roberts H, Mol BW (2012): Progesterone for premenstrual syndrome. Cochrane Database Syst Rev. 2012 Mar 14;3:CD003415

    PubMed  Google Scholar 

  • Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ (2000): A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 133: 933–1001

    Article  CAS  PubMed  Google Scholar 

  • Gronich N, Lavi I, Rennert G (2011): Higher risk of venous thrombosis associated with drospirenone-containing oral contraceptives: a population-based cohort study. CMAJ 183: E1319–1325

    Article  PubMed  PubMed Central  Google Scholar 

  • Heiss G, Wallace R, Anderson GL, Aragaki A, Beresford SA, Brzyski R, Chlebowski RT, Gass M, LaCroix A, Manson JE, Prentice RL, Rossouw J, Stefanick ML; WHI Investigators (2008): Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA 299: 1036–1045

    Article  CAS  PubMed  Google Scholar 

  • Hilbert-Walter A, Büttner R, Sieber C, Bollheimer C (2013): Testosteron im Alter: ein Update. Dtsch Med Wochenschr 137: 2117–2122

    Google Scholar 

  • Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C (1995): Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 346: 1589–1593

    Article  CAS  PubMed  Google Scholar 

  • Keaney JF, Solomon CG (2016): Postmenopausal hormone therapy and atherosclerosis—Time is of the essence. N Engl J Med 374: 1279–1280

    Article  CAS  PubMed  Google Scholar 

  • Kemmeren JM, Algra A, Grobbee DE (2001): Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. Brit Med J 323: 1–9

    Article  Google Scholar 

  • LaCroix AZ;Chlebowski RT;Manson JE;Aragaki AK;Johnson KC;Martin L;Margolis KL;Stefanick ML;Brzyski R;Curb JD;Howard BV;Lewis CE;Wactawski-Wende J; WHI Investigators (2011): Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA 305: 1305–1314

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lidegaard Ø, Nielsen LH, Skovlund CW, Skjeldestad FE, Løkkegaard E (2011): Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001–9. BMJ 25;343:d6423

    Article  Google Scholar 

  • Lidegaard O, Nielsen LH, Skovlund CW, Løkkegaard E (2013): Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001-10. BMJ 344: e2990

    Article  Google Scholar 

  • Long CY, Liu CM, Hsu SC, Wu CH, Wang CL, Tsai EM (2006): A randomized comparative study of the effects of oral and topical estrogen therapy on the vaginal vascularization and sexual function in hysterectomized postmenopausal women. Menopause 13: 737–743

    Article  PubMed  Google Scholar 

  • Manson JE, Chlebowski RT, Stefanick ML, Aragaki AK, Rossouw JE, Prentice RL, Anderson G, Howard BV, Thomson CA, LaCroix AZ, Wactawski-Wende J, Jackson RD, Limacher M, Margolis KL, Wassertheil-Smoller S, Beresford SA, Cauley JA, Eaton CB, Gass M, Hsia J, Johnson KC, Kooperberg C, Kuller LH, Lewis CE, Liu S, Martin LW, Ockene JK, O’Sullivan MJ, Powell LH, Simon MS, Van Horn L, Vitolins MZ, Wallace RB (2013): Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA 310: 1353–1368

    Article  CAS  PubMed  Google Scholar 

  • McFadyen IJ, Forrest APM, Raab GM, Macintyre CCA (1989): Progesterone cream for cyclic breast pain. Brit Med J 289: 931

    Article  Google Scholar 

  • Million Women Study Collaborators (2003): Breast cancer and hormone-replacement in the Million Women Study. Lancet 362: 419–427

    Article  Google Scholar 

  • Million Women Study Collaborators (2005): Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 365: 1543–1551

    Article  Google Scholar 

  • Million Women Study Collaborators (2007): Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet 369: 1703–1710

    Article  Google Scholar 

  • Modelska K, Cummings S (2002): Tibolone for postmenopausal women: systematic review of randomized trials. J Clin Endocrinol Metab 87:16–23

    Article  CAS  PubMed  Google Scholar 

  • Nelson HD (2004): Commonly used types of postmenopausal estrogen for treatment of hot flashes: scientific review. JAMA 291: 1610–1620

    Article  CAS  PubMed  Google Scholar 

  • Oddsson K, Leifels-Fischer B, de Melo NR, Wiel-Masson D, Benedetto C, Verhoeven CH, Dieben TO (2005): Efficacy and safety of a contraceptive vaginal ring (NuvaRing) compared with a combined oral contraceptive: a 1-year randomized trial. Contraception 71: 176–182

    Article  CAS  PubMed  Google Scholar 

  • Ravdin PM, Cronin KA, Howlader N, Berg CD, Chlebowski RT, Feuer EJ, Edwards BK, Berry DA (2007): The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 356: 1670–1674

    Article  CAS  PubMed  Google Scholar 

  • Royal College of General Practitioners Oral Contraception Study (1981): Further analysis of mortality in oral contraceptive users. Lancet I: 541–546

    Google Scholar 

  • Schubert M, Minnemann T, Hubler D, Rouskova D, Christoph A, Oettel M, Ernst M, Mellinger U, Krone W, Jockenhövel F (2004): Intramuscular testosterone undecanoate: pharma cokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism. J Clin Endocrinol Metab 89: 5429–5434

    Article  CAS  PubMed  Google Scholar 

  • Spitzer WO, Lewis MA, Heinemann LAJ, Thorogood M, MacRae KD (1996): Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Brit Med J 312: 83–88

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Stuenkel CA, Davis SR, Gompel A, Lumsden MA, Murad MH, Pinkerton JV, Santen RJ (2015): Treatment of symptoms of the menopause: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 100: 3975–4011

    Article  CAS  PubMed  Google Scholar 

  • World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception (1995): Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 346: 1582–1588

    Article  Google Scholar 

  • Womens Health Initiative Steering Committee (2004): Effect of conjugated equine estrogen in postmenopausal women with hysterectomy. The Women’s Health Initiative randomized controlled trial. JAMA 291: 1701–1712

    Article  Google Scholar 

  • Writing Group for the Women’s Health Initiative Investigators (2002): Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288: 321–333

    Article  Google Scholar 

  • Yang LP, Plosker GL (2012): Nomegestrol acetate/estradiol: in oral contraception. Drugs 72: 1917–1928

    Article  CAS  PubMed  Google Scholar 

  • Zbuk K, Anand SS (2013): Declining incidence of breast cancer after decreased use of hormone-replacement therapy: magnitude and time lags in different countries. J Epidemiol Community Health 66: 1–7

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pharmakologisches Institut, Universität Heidelberg, Neuenheimer Feld 366, 69120, Heidelberg

    Prof. em. Dr. med. Ulrich Schwabe

  2. Gynäkologische Endokrinologie und Fertilitätsstörungen, Universitäts-Frauenklinik, Neuenheimer Feld 440, 69120, Heidelberg

    Prof. Dr. med. Thomas Strowitzki

Authors
  1. Prof. em. Dr. med. Ulrich Schwabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. med. Thomas Strowitzki
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Pharmakologisches Institut, Universität Heidelberg, Im Neuenheimer Feld 366, 69120, Heidelberg

    Ulrich Schwabe

  2. Bachstraße 29, 50858, Köln

    Dieter Paffrath

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Schwabe, U., Strowitzki, T. (2016). Sexualhormone. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2016. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-50351-5_44

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-50351-5_44

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-50350-8

  • Online ISBN: 978-3-662-50351-5

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation